In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses targeted therapy with FLT3 and IDH1/2 inhibitors in AML, with a focus on the nursing perspective. Topics include:

Approved and emerging treatment options for FLT3-mutated AML
Management of adverse events associated with FLT3 inhibitors
Therapies for IDH1- and IDH2-mutated AML
Identifying and managing differentiation syndrome associated with IDH1/2 inhibitors

Presenters:

Sarah M. Tinsley, PhD, APRN, AOCN
Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations